Precision of IMED-4 Lung Fluid Measurements

Dyspnea Clinical Trial

Official title:

Precision of IMED-4 Lung Fluid Measurements

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02187770
• Other study ID #: CP-000040
• Status: Completed
• Phase: N/A
• First received: July 7, 2014
• Last updated: October 13, 2015
• Start date: July 2014
• Est. completion date: October 2015

Study information

• Verified date: October 2015
• Source: Intersection Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.

Description:

The study will evaluate if the IMED-4 system has the precision to detect a clinically significant change in lung fluid status for patients with confirmed acute heart failure syndrome with pulmonary congestion. Changes in lung fluid in acute heart failure syndrome are difficult to diagnose and evaluate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: October 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Diagnosed with acute heart failure syndrome with pulmonary congestion defined by a Brain natriuretic peptide (BNP) >350 pg/mL or N-terminal pro-brain natriuretic peptide (NT-pro BNP) >1500 pg/mL and any one of the following:

1. PCWP >25mmHg

2. Dyspnea at rest in a recumbent sitting position (30 to 45 degrees), which has worsened within the past week

3. Radiological evidence of CHF on a chest X-ray

4. Physical exam as evidence for pulmonary congestion:

i. Presence of an S3 heart sound ii. Lung rales/crackles/crepitations

2. Age greater than or equal to (=) 18

3. Ability to reliably carry out self-assessment of symptoms

4. Willingness, ability and commitment to participate in index and follow-up IMED-4 recordings

EXCLUSION Criteria

1. Known active myocarditis, obstructive hypertrophic cardiomyopathy, constrictive pericarditis, uncorrected clinically significant primary valvular disease

2. Clinical diagnosis of acute coronary syndrome meeting any 2 of the following 3 criteria:

1. Prolonged chest pain at rest, or an accelerated pattern of angina

2. Electrocardiogram changes indicative of ischemia or myocardial injury

3. Serum troponin >3 times upper limit of lab normal

3. Clinically-suspected acute mechanical cause of ADHF (e.g., papillary muscular rupture); the diagnosis need not be confirmed by imaging or cardiac catheterization

4. Estimated Glomerular Filtration Rate: eGFR <30mL/min/1.73m

5. Known vasculitis, active infective endocarditis, or suspected infections including pneumonia, acute hepatitis, systemic inflammatory response syndrome, or sepsis

6. Body temperature =38°C just prior to enrollment

7. Acute or chronic respiratory disorder (e.g. severe chronic obstructive pulmonary disease (COPD)) or primary pulmonary hypertension sufficient to cause dyspnea at rest, which may interfere with the ability to interpret dyspnea assessments or hemodynamic measurements

8. Total Albumin <2.5 g/dL

9. Patients requiring mechanical circulatory support

10. Pregnancy or lactation

11. Patients who have tattoos and/or non-intact skin directly under the electrode sensor position

12. Patients who have had past allergic reactions to medical grade adhesives

13. Patients who have had a lung lobectomy

14. Patients who decline to have their backs photographed with the IMED-4 device in position

15. Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectance, etc.)

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Heart Failure Syndrome
• Dyspnea
• Pulmonary Congestion

Intervention

Device:
• IMED-4
Non invasive recording electrode used to assess lung fluid

Locations

Country	Name	City	State
United States	Mass General Hospital	Boston	Massachusetts
United States	Ohio State University	Columbus	Ohio
United States	Henry Ford Hospital	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Intersection Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung Fluid Status	IMED 4 is a new device to measure lung fluid status by assessing how wet or dry the lungs are	Up to 1 year	No